In a report released yesterday, Ann Hynes from Mizuho Securities reiterated a Buy rating on Syneos Health (SYNH – Research Report), with a price target of $94.00. The company’s shares closed last Friday at $70.91, close to its 52-week low of $66.73.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of 8.4% and a 56.3% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Quest Diagnostics, and Molina Healthcare.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Syneos Health with a $92.86 average price target.
The company has a one-year high of $104.18 and a one-year low of $66.73. Currently, Syneos Health has an average volume of 779.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syneos Health, Inc. provides outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded on August 13, 2010 and is headquartered in Morrisville, NC.
Read More on SYNH:
- Robert W. Baird Keeps a Buy Rating on Bj’s Wholesale Club Holdings (BJ)
- Analysts Are Bullish on Top Healthcare Stocks: Provention Bio (PRVB), Applied Molecular Transport (AMTI)
- Evercore ISI Thinks Anheuser-Busch Inbev Sa’s Stock is Going to Recover
- Chubb (CB) Gets a Buy Rating from Evercore ISI
- RBC Capital Maintains Their Hold Rating on New Relic (NEWR)